Reaney, Matthew http://orcid.org/0000-0003-2918-722X
Addepalli, Prithvi
Allen, Veleka
Spertus, John A. http://orcid.org/0000-0002-2839-2611
Dolan, Chantal
Sehnert, Amy J. http://orcid.org/0000-0003-1912-1710
Fine, Jennifer T.
Funding for this research was provided by:
MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb
Article History
Accepted: 16 May 2022
First Online: 20 June 2022
Declarations
:
: Support of this analysis and manuscript was provided by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. Medical writing support was provided by IQVIA and PharmaGenesis Oxford Central, with funding from MyoKardia, Inc.
: MR, PA, and VA are employees of IQVIA and have received funding from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for work performed on this study. JAS has served as a consultant and holds a research grant from MyoKardia, Inc.; he also provides consultative services for Bayer, Janssen, Merck, Novartis, Pfizer, and Terumo; JAS owns the copyright to the Kansas City Cardiomyopathy Questionnaire. CD is a consultant for Bristol Myers Squibb and the following companies: Alexion Pharmaceuticals, Coagulant Therapeutics, Elekta, Genentech, Gilead Sciences, Global Blood Therapeutics, Lyell Immunopharma, Portola Pharmaceuticals, Inc., Puma Biotechnology, and Regenxbio Inc. AJS is an employee of MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, and holds stocks. JTF is an employee of MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, and holds stocks/options.
: BMS policy on data sharing may be found at ExternalRef removed.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Matthew Reaney, Veleka Allen, and Amy Sehnert. All authors contributed to the drafting and revision of the manuscript. All authors approved the final manuscript.
: All aspects of the EXPLORER-HCM study and its analysis were conducted in compliance with the Health Insurance Portability Accountability Act of 1996 (USA). Institutional review board and ethics committee approvals were obtained prior to participant enrollment. Study protocols were approved by a US institutional review board: The New England Independent Review Board (197 First Avenue, Suite 250, Needham, MA 02494); appropriate approvals were also obtained for each participating country. The study and its analysis fully adhered to the ethical principles of the Declaration of Helsinki and the specifications of the International Council on Harmonisation and Good Clinical Practice.
: All participants provided informed (written and verbal) consent prior to their participation. All data is deidentified and no individual patient is presented; therefore, consent to publish was not required.